Livros e Capítulos de Livros - LIM/60
URI Permanente para esta coleção
A coleção de Livros e Capítulos de Livros reúne capítulos e resumos de obras produzidas por autores do sistema FMUSP-HC que inclui a Faculdade de Medicina da Universidade de São Paulo (FMUSP), o Hospital das Clínicas da FMUSP e demais institutos associados.
Navegar
Submissões Recentes
- Serum Amyloid A Amyloidosis(2023) MENDONçA, L. O.; SZOR, R. S.Systemic amyloidosis is a heterogeneous group of disorders caused by the deposition of misfolded protein fibrils in the extracellular space of tissues. Among the 36 amyloid protein fibrils identified to date, serum amyloid A is the causative protein of AA amyloidosis. Clinical presentations of almost all amyloidosis are similar and are nonspecific about what impacts directly in disease early recognition, diagnosis, and treatment. Chronic and persistent systemic inflammation driven by regulatory cytokines such as tumor necrosis factor, IL-1, and IL-6 is a reasonable explanation for AA amyloidosis, although the exact mechanism is still unknown. The discovery of the monogenic autoinflammatory disease and its relation to AA amyloidosis brought to light therapeutic choices for the IL-1-mediated AA amyloidosis. This chapter is focused on the many aspects of AA amyloidosis. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.
bookPart Erros inatos da imunidade(2023) MARINHO, Ana Karolina Barreto BersellibookPart Febre na unidade de terapia intensiva(2023) ZANELLA, Luiz Gonzaga Francisco de Assis Barros D´Elia- Drug Hypersensitivity(2019) CASTELLS, M.; BONAMICHI-SANTOS, R.Identifying drug-hypersensitive patients protects them from reexposure to culprit medications and permits access to desensitization procedures when needed and indicated. Identifying patients who are not in fact hypersensitive means they can avoid receiving second-line therapies with their associated increased costs and resource requirements. The vast majority of patients with a history of penicillin allergy have negative results on skin testing and do not react during a challenge or during further courses of penicillin, but there is a lack of standardized reagents approved by the US Food and Drug Administration (FDA) for the diagnosis of allergy to the majority of antibiotics and other drugs. Central to the evaluation of patients with drug hypersensitivity is an understanding of the pathophysiology of the reactions. Genotype studies of patients with severe hypersensitivity reactions, including drug-induced reactions with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrosis (TEN), have uncovered predisposing specific HLA alleles permitting identification of targeted populations and protection against these reactions. Systematic utilization of available markers of immune cell activation, such as tryptase (the major mast cell protease released during anaphylactic IgE- and non-IgE–mediated reactions) can provide useful diagnostic information and help guide the treatment and management of drug reactions.Reactions to drugs are an important source of morbidity and mortality and constitute a major hazard in the practice of medicine. We have an incomplete understanding of the mechanisms of the reactions, few tools for their diagnosis and/or prevention, and limited treatment options. With the introduction of new and better medications to treat cancer, chronic inflammatory diseases, and infections, there has been a parallel increase in the frequency of drug allergy and hypersensitivity. Although these new, targeted therapies offer increased survival and quality of life, repeated exposures to small molecules and monoclonal antibodies (mAbs) with immunogenic and allergenic capacity have increased the rate of sensitizations and reactions. Drug hypersensitivity prevents patients from receiving first-line therapy, and doctors have few guidelines on how to diagnose and address these potentially life-threatening reactions. © 2019 Elsevier Ltd. All rights reserved.
bookPart 0 Citação(ões) na Scopus Occupational allergy in elite runners(2014) TEIXEIRA, R. N.; ROMANHOLO, B. S.; AGONDI, R. C.; PINTO, A. F.; MARTINS, M. de Arruda; CARVALHO, C. R. F.Background: The prevalence of allergy, asthma and airwayinflammation and hyperresponsiveness in elite athletes has increased overthe years and appears to vary between sport modalities. Although allergicand respiratory diseases have been extensively studied in enduranceathletes, especially swimmers and winter sports athletes, the prevalencein elite runners remains unknown.Objective: The aims of this study were to screen allergy symptoms inelite runners and to evaluate the airway responsiveness and airwayinflammatory cells in these athletes.Methods: One hundred and thirty elite runners were invited tocomplete the Allergy Questionnaire for Athletes (AQUA©), a validatedquestionnaire to screen allergy in athletes, in addition to answeringquestions related to training history, running distance per week and bestrace time in a marathon or half-marathon. A subgroup of 36 nonasthmaticathletes also performed the methacholine challenge test,sputum induction and cardiopulmonary exercise testing. Airwayinflammation was quantified via cellular airway infiltration.Results: The presence of allergy was based on the AQUA© totalscore, and athletes were classified as either AQUA+ or AQUA- (a score=5 or <5, respectively). Sixty-one athletes (60%) reported allergysymptoms, and no significant differences between the groups (AQUA+and AQUA-) were observed regarding gender, age, running experience,weekly training volume or best performance time in a half-marathon ormarathon (p>0.05). Most athletes presented airway inflammation witheosinophilic predominance (23.6%); however, only 8.3% of the eliterunners had a positive response to methacoline challenge.Conclusions: Our study demonstrated that elite runners have a highprevalence of allergy and eosinophilic airway inflammation withoutevidence of airway hyperresponsiveness; this finding was independent ofgender, age, quantity of training and performance. © 2014 Nova Science Publishers, Inc. All rights reserved.bookPart Imunoterapia na alergia alimentar(2022) ANAGUSKO, Claudia Leiko Yonekura; MENDONçA, Juliana Guimarães de; YANG, Ariana CamposbookPart Provas de provocação com alimentos(2022) YANG, Ariana Campos; CORDóVA, Pablo Michael TorresbookPart Glicocorticoides(2022) LIMA, Fabiana Mascarenhas Souza; BARROS, Myrthes Anna Maragna ToledobookPart Imunoterapia alérgeno-específica(2022) GALVãO, Clóvis Eduardo Santos; MACEDO, Priscilla Rios CordeirobookPart Alergias ocupacionais cutâneas(2022) LOPES, Mariele Morandin; GRECCO, OctaviobookPart Definição e classificação de anafilaxia(2022) WATANABE, Alexandra SayuribookPart Alergias ocupacionais respiratórias(2022) GALVãO, Clóvis Eduardo Santos; LIMA, Cynthia Mafra Fonseca debookPart Tratamento e prevenção da anafilaxia(2022) WATANABE, Alexandra Sayuri; LIMA, Cynthia Mafra Fonseca debookPart Testes de contato(2022) ANAGUSKO, Claudia Leiko Yonekura; GRECCO, OctaviobookPart Testes cutâneos de leitura imediata e tardia(2022) GALVãO, Clóvis Eduardo Santos; MORAES, PriscilabookPart Anamnese especializada(2022) LOPES, Mariele Morandin; ANTILA, Henrikki Gomes; BARROS, Myrthes Anna Maragna ToledobookPart Outras causas de anafilaxia(2022) GALVãO, Clóvis Eduardo Santos; LIMA, Cynthia Mafra Fonseca debookPart Dermatites de contato(2022) LOPES, Mariele Morandin; MOTTA, Antônio Abílio; GRECCO, OctaviobookPart Angioedema(2022) MOTTA, Antônio Abílio; AGONDI, Rosana Câmara